Most Read Articles
Fiel Soliven, 18 Mar 2015
The connection between prediabetes, diabetes, and risk of hepatocellular carcinoma (HCC) in HBsAg and anti-HCV seronegative patients, as well as the association between fasting glucose and HCC were examined in this study.
01 Feb 2016
Long-term ezetimibe improves lipid metabolism in dyslipidaemic patients with hepatobiliary disease, based on a study.
01 Feb 2016
Use of gadoxetate disodium for functional MRI can obtain useful data on hepatobiliary diseases, an article states.
Tristan Manalac, 14 Sep 2017
An 8-week regimen of sofosbuvir-velpatasvir-voxilaprevir combination is not noninferior to a 12-week regimen of sofosbuvir-velpatasvir for patients with chronic hepatitis C virus (HCV) infection, report two recent phase 3 open-label trials.

Treatment of alcoholic hepatitis – Role of S-adenosyl-L-methionine (SAMe)

09 Nov 2016
At a recent Abbott-sponsored satellite symposium held during the GUT Congress 2016 in Kuala Lumpur, an expert from India presented on the management of alcoholic liver disease, and illustrated the role of SAMe as a complementary therapy.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Fiel Soliven, 18 Mar 2015
The connection between prediabetes, diabetes, and risk of hepatocellular carcinoma (HCC) in HBsAg and anti-HCV seronegative patients, as well as the association between fasting glucose and HCC were examined in this study.
01 Feb 2016
Long-term ezetimibe improves lipid metabolism in dyslipidaemic patients with hepatobiliary disease, based on a study.
01 Feb 2016
Use of gadoxetate disodium for functional MRI can obtain useful data on hepatobiliary diseases, an article states.
Tristan Manalac, 14 Sep 2017
An 8-week regimen of sofosbuvir-velpatasvir-voxilaprevir combination is not noninferior to a 12-week regimen of sofosbuvir-velpatasvir for patients with chronic hepatitis C virus (HCV) infection, report two recent phase 3 open-label trials.